Annexin A1 in neurological disorders: Neuroprotection and glial modulation

Autor(es)

Ferreira, Luiz Philipe de Souza ; da Silva, Rafael Andre ; Borges, Pamela Pacassa ; Xavier, Luana Filippi ; Scharf, Pablo ; Sandri, Silvana ; Oliani, Sonia M. ; Farsky, Sandra H. P. ; Gil, Cristiane D.

• Tipo de documento: Artigo Científico
• Fonte: PHARMACOLOGY & THERAPEUTICS; v. 267, p. 10-pg., 2025-03-01.

Resumo

Neurological disorders, such as neurodegenerative and neuroinflammatory diseases, have contributed significantly to global disability, even considering the rising life years expectations. Therefore, prevention, early diagnosis, and therapeutic alternatives have been essential to avoid the future collapse of health public systems. Annexin A1 (ANXA1), a Ca2 + -dependent protein, is a promising therapeutic candidate for neurological disorders. ANXA1, found in neurons and glia, displays roles in physiological and pathological processes. Despite ANXA1 undoubtedly maintains the blood-brain barrier (BBB) integrity, this review will focus on ANXA 1 roles in neurons and glial cells. In neurons, the cytoplasmic expression of ANXA1 is associated with apoptosis, while its nuclear translocation is linked to ischemic neuronal death. Interactions with S100A11, the Tat-NTS peptide, and other molecules, modulate this translocation, suggesting potential therapeutic interventions. ANXA1 expressed on microglia modulates inflammation and efferocytosis. Post-translational modifications, such as SUMOylation, guide the role of ANXA1 in microglia polarization and neuroprotection. In addition, ANXA1 in astrocytes responds to inflammatory stimuli by influencing cytokine release. A comprehensive understanding of the intricate mechanisms of ANXA 1 in neurons and glial cells reveals promising therapeutic strategies to alleviate neuronal damage in neurological diseases. (c) 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies. (AU)

• Processo FAPESP: 22/11779-8 - Mecanismos tóxicos dos produtos fumígenos sobre a produção e mobilização de neutrófilos em condições normais e na vigência de artrite reumatoide
• Beneficiário: Pâmela Pacassa Borges
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 22/12027-0 - Proteína anexina a1 na inflamação da retinopatia diabética
• Beneficiário: Rafael André da Silva
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 21/00270-4 - Papel da proteína Anexina A1 em modelo experimental da Doença de Parkinson
• Beneficiário: Luiz Philipe de Souza Ferreira
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 22/02327-6 - Impacto do tratamento farmacológico com o peptídeo mimético da Anexina A1 em modelo experimental da Doença de Parkinson
• Beneficiário: Cristiane Damas Gil
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 22/14025-4 - Efeitos do vapor de tabaco aquecido, nicotina e exposições à fumaça de cigarro nas interações neuroimunes de C. elegans e na defesa do hospedeiro
• Beneficiário: Pablo Rhansan dos Santos Scharf
• Modalidade de apoio: Bolsas no Exterior - Estágio de Pesquisa - Doutorado